medigraphic.com
ISSN 0188-9796 (Print)

2005, Number 1

<< Back Next >>

Rev Endocrinol Nutr 2005; 13 (1)

Position of the SMNE over the management of metabolic syndrome (2nd part)

Gómez PFJ, Ríos TJM, Aguilar-Salinas CA, Lerman GI, Rull JA

Language: Spanish
References: 119
Page: 9-23
PDF size: 151.68 Kb.


Text Extraction

No abstract


REFERENCES

  1. McCarthy M. Big Jump in diabetes in USA linked to rise in obesity. Lancet 2000; 356: 833.

  2. Frankish H. Obesity and diabetes epidemics show no sign of abating. Lancet 2001; 358: 896.

  3. Meigs JB. The metabolic syndrome. BMJ 2003; 327: 61-62.

  4. Grundy SM, Brewer HB, Cleeman JI et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.

  5. Gramlich T, Kleiner DE, McCollough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004; 35: 196-199.

  6. Harrison SA, Torgerson S, Hayashi PH. The natural history on nonalcoholic fatty liver disease a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042.

  7. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-1219.

  8. Petersen KF, Dufour S, Befroy D, García R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. 2004; 350: 664-671.

  9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.

  10. Bloomgarden ZT. Definitions of the insulin resistance syndrome. Diabetes Care 2004; 27: 824-830.

  11. Haffner SM, González C, Hazuda HP, Mitchell BD, Monterrosa A, Stern MP Is microalbuminuria part of the prediabetic state?. The México City Diabetes Study. Diabetología 1993; 36: 1002-1006.

  12. Fernández-Real JM, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana-Abella R et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998; 21: 62-68.

  13. Happ M, Fritsche A, Mensing HJ, Haring HU, Stumvoll M. Association of high serum ferritin concentrations with glucose intolerance and insulin resistance in healthy people. Ann Intern Med 2003; 139: 869-871.

  14. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Tehouwer CD. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy non-obese subjects. Atherosclerosis 1998; 139: 197-198.

  15. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, D´Agostino RB, Wilson PWF. Fasting plasma homocysteine levels in the insulin resistance syndrome. Diabetes Care 2001; 24: 1403-1410.

  16. Pouwells MJJ, Heijer Md, Blom HJ, Tack CJ, Hermus AR. Improved insulin sensitivity and metabolic control in type 2 diabetes does not influence plasma homocysteine. Diabetes Care 2003; 26: 1637-1638.

  17. Balletshofer BM, Ritting K, Enderle MD et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784.

  18. James RW. Diabetes and other coronary heart disease risk equivalents. Curr Opin in Lipidol 2001; 12: 425-431.

  19. Vehkavaara S, Makimattila S, Schelnska A et al. Insulin therapy improves endotelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 545-550.

  20. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington diabetes survey. Lancet 1988; 2: 53033.

  21. Kuusinsto J, Mykkanen l, Pyorala K, Laakso M. Hyperinsulinemic microalbuminuria. A new risk indicator for coronary artery disease. Circulation 1995; 91: 831-837.

  22. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Valles V, Ríos-Torres JM, Franco A, Olais G, Rull JA, Sepúlveda J. Prevalence of the metabolic syndrome in México: results of a population-based survey. Arch Med Res 2004; 35: 76-81.

  23. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Ríos-Torres JM, Franco A, Olais G, Rull JA, Sepúlveda J. Analysis of agreement between the World Health Organization criteria and the National Cholesterol Education Program-III definition of the metabolic syndrome. Diabetes Care 2003; 26: 1635.

  24. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with type 2 diabetes. Diabet Med 2004; 21: 383-387.

  25. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, Klein RL, Garvey WT. Critical evaluation of Adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004; 27: 978-983.

  26. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26: 575-581.

  27. Meigs JB, Wilson PWF, Nathan DM, Dágostino RB, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003; 52: 2160-2167.

  28. Hu G, Qiao Q, Tuomilehto J, Balkau B, Boch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Int Med 2004; 164: 1066-1076.

  29. Anand SS, Yusuf S, Devanesen S, Teo KK, Montague PA, Kelemen L, Yi C, Lonn E, Gerstein H, Hegele RA, McQueen M. Differences in risk factors, ateroesclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic Groups (SHARE). Lancet 2000; 356: 279-284.

  30. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002: 356-359.

  31. Aguilar-Salinas CA, Olais G, Valles V, Rios-Torres JM, Gómez-Perez FJ, Rull JA, Rojas R, Franco A, Sepulveda J. High prevalence of low cholesterol concentrations and mixed hiperlipidemia in a mexican nationwide survey. J Lip Res 2001; 42: 1298-1307.

  32. Nestel P. Metabolic syndrome; the new cardiovascular target. Curr Opin Lipidol 2004; 15: 1-3.

  33. Sattar N, Gaw A, Scerbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419.

  34. Yamamoto-Kimura L, Zamora-González J, García de la Torre G, Cardoso-Saldana G, Fajardo-Gutierrez A, Ayala-Barajas C, Posadas-Romero C. Prevalence of high blood pressure and associated coronary risk factors in an adult population of Mexico City. Arch Med Res 1998; 29: 341-349.

  35. Aguilar-Salinas CA, Velásquez Monroy O, Gomez-Perez FJ, González Chávez A, Lara-Esquerra A, Molina Cuevas V, Rull JA, Tapia R. Characteristics of patients with type 2 diabetes in México: Results from a large population-based nationwide survey. Diabetes Care 2003; 26: 2021-2026.

  36. Hu, MF, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC, Diet, Lifestyle, and the Risk of Type 2 Diabetes Mellitus in Women. N Engl J Med 2001; 345: 790-797.

  37. Gross LS, LiL, Ford ES, Liu S. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr 2004; 79: 774-779.

  38. Wolever TMS, Cmpbell JF, Geleva D, Anderson GH. High fiber cereal reduces postprandial insulin respponses in hyperinsulinemic but not normoinsulinemic subjects. Diabetes Care 2004; 27: 1281-1285.

  39. Pereira M, Jacobs DR, Pins JJ, Raatz SK, Gross MD, Slavin JL, Seaquist ER. Am J Clin Nutr 2002; 75: 848-855.

  40. Ford ES, Liu S. Glycemic index and serum high density lipoprotein colesterol concentration among US adults. Arch Intern Med 2001; 161: 572-576.

  41. Mc Laughlin Abbasi F, Kim HS. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy obese women. Metabolism 2001; 50: 795-800.

  42. Goodpaster BH, Katsiaras A, Kelley DE. Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes 2003; 52: 2191-2197.

  43. Smith SC, Jackson R, Pearson TA; Fuster V, Yusuf S, Faergeman O, Wood D, Alderman M, Horgan J, Home P, Hunn M, Grundy SM. Principles for National and Regional Guidelines on Cardiovascular Disease Prevention. A scientific Statement from the World Heart and Stroke Forum. Circulation 2004; 109: 3112-3121.

  44. Grundy SM, Cleeman JI, Merz NB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program. Adult treatment Panel III Guidelines. Circulation 2004; 110: 227-239.

  45. American College of Endocrinology. Position statement on the insulin resistance syndrome. Endocrine Practice 2003; 9 (Suppl. 2): 2346-2352.

  46. SP Wamala, J Lynch, M Horsten, MA Mittleman, K Schenck-Gustafsson and K Orth-Gomer. Education and the metabolic syndrome in women. Diabetes Care 2003; 22: 1999.

  47. Maison P, Byrne C D, Hales CN, Day N E Wareham N J. Do Different Dimensions of the Metabolic Syndrome Change Together Over Time? Diabetes Care 2001; 24: 1758-1763.

  48. Executive summary of the third report of the NCEP Expert Panel on detection evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001; 285: 2485-2497.

  49. Expert Committee on the Diagnosis and Classification of diabetes mellitus. Report of the expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26; 3160-3167.

  50. Schriger DL, Lorber B. Lowering the cut point for impaired fasting glucose. Diabetes Care 2004; 27: 592-595.

  51. Grundy CM. Prevention and Management of dyslipidemia and the metabolic syndrome in obese patients. Chap. 7. In: Handbook of obesity. 2nd. Edition. Bray GA, Bouchard C. (Eds.). Marcel Dekker, Inc. 2004

  52. Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Savoye AK, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346: 802.

  53. The Practical Guide: Identification, Evaluation and treatment of Overweight and Obesity in Adults. US Department of Health and Human Services. Public Health Service, National institutes of Health, National Heart Lung, and Blood Institute. NIH Publication No. 00-4084, October 2000.

  54. Sánchez-Castillo CP, Velásquez-Monroy O, Berber A, Lara-Esqueda A, Tapia-Conyer R, James WP; Encuesta Nacional de Salud (ENSA) 2000 Working Group. Anthropometric cut-off points for predicting chronic diseases in the Mexican National Health Survey. Obes Res 2003; 11: 442-451.

  55. Palaniappan L, Carnethon MR, Wang Y, Hanley AJG, Fortmann SP, Haffner SM, Wagenknecht L, DRPH Predictors of the Incident Metabolic Syndrome in Adults. Diabetes Care 2004; 27: 788-793.

  56. Wei N, Gaskill SP, Haffner SM, Stern MP. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans--a 7-year prospective study. Obesity Research 1997; 5: 16-23..

  57. Knowler WC, Barrett-Connors E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifetime intervention or metformin. N Engl J Med 2002; 346: 393-403.

  58. Knowler WC, Narayan KMV, Hanson RL, Nelson RG, Bennett PH, Tuomilehto J et al. Preventing non-insulin-dependent diabetes mellitus. Diabetes 1995; 44: 483-488.

  59. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537–544.

  60. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350.

  61. Vegt F, Dekker JM, Hienkens E, Jostense PJ, Stohower CD et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population. The Hoorn study. JAMA 2001; 285: 2109-2113.

  62. Venkat Narayan KM, Imperatore G, Benjamin Stephanie M, Engelgau MM. Targeting people with pre-diabetes. BMJ 2002; 325: 403-404.

  63. Janz NK, Mecker MH. The health belief model: a decade later. Health Educ Q 1984; 2: 1-47.

  64. Rogers EM. Lessons for guidelines from the diffusion of innovations. JT Comm J Qual Improv 1995; 21: 324-328.

  65. Baughcum AE, Burklow KA, Deeks CM, Powers SW, Whitaker RC Maternal feeding practices and childhood obesity: a focus group study of low income mothers. Arch Pediatr Adolesc Med 1998; 152: 1010-1014.

  66. Wardle J, Sanderson S, Guthrie CA, Rapoport L, Plomin R. Parental feeding style and the inter-generational transmission of obesity risk. Obes Res 2002; 10: 453-462.

  67. Laessle RG, Uhl H, Lindel B. Parental influences on eating behavior in obese and non-obese adolescents. Int J Eat Disord 2001; 30: 447-453.

  68. Spruijt-Metz D, Lindquist CH, Birch LL, Fisher JO, Goran MI. Relation between mothers´ child-feeding practices and children’s adiposity. Am J Clin Nutr 2002; 75: 581-586.

  69. Larson DE, Hunter GR, Williams MJ, Kekes-Szabo T, Nyikos I, Goran MI. Dietary fat in relation to body fat and intra-abdominal adipose tissue a cross-sectional analysis. Am J Clin Nutr 1996; 64: 677-684.

  70. Weintraub M, Sundaresan PR, Mann M et al. Long-term weight control: the National Heart Lung and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992; 51(Suppl. 5): 581-646.

  71. Goldstein DJ, Potvin JH. Long-term weight loss: The effect of pharmacological agents. Am J Clin Nutr 1994; 60: 647-657.

  72. AACE/ACE Position statement on the prevention, diagnosis and treatment of obesity.(1998 revision). Endocrine Practice 1998; 4: 297-350.

  73. Janssen I, Fortier A, Hudson R, Ross R. Effects of an energy-restrictive diet with or without exercise on abdominal fat, intermuscular fat, and metabolic risk factors in obese women. Diabetes Care 2002; 25: 431-438.

  74. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 2004; 20: 295-304.

  75. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook GJ, Levy Y. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004; 28: 674-679.

  76. Reaven GM. Do carbohydrate diets prevent the development or attenuate the manifestations (or both) of syndrome X?. A view point strongly against. Curr Opin Lipidol 1997; 8: 23-27.

  77. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. Arterioscler Thromb 1992; 12: 911-919.

  78. Gardner CD, Kraemer HC. Monounsaturated versus polyunsaturated dietary fat and serum lipids. A meta-analysis. Arterioscler Thromb Vasc Biol 1995; 15: 1917-1927.

  79. Garg A. High monounsaturated-fat diets for patients with diabetes mellitus: a metanalysis. Am J Clin Nutr 1998; 67: 577S-582S.

  80. Parks EJ, Hellerstein MK. Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 2000; 71: 412-433.

  81. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002; 25(Suppl. 1): S50-S60.

  82. Bouché C, Rizkalla SW, Luo J, Veronese A, Pacer N, Fouquet C, Lang V, Slama G. Five-week, low-glycemic index diet decreases total fat mass and improves lipid profile in moderately overweight non diabetic men. Diabetes Care 2002; 25: 822-828.

  83. Ebbeling CB, Leidig MM, Sinclair KB et al. A reduced-glycemic load diet in the treatment of adolescent obesity. Arch Pediatr Adolesc Med 2003; 157: 773-779.

  84. Noakes M, Clifton P. Weight loss, diet composition and cardiovascular risk. Curr Opin in Lipidol 2004; 15: 31-35.

  85. McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PWF, Jacques PF. Carbohydrate nutrition, insulin resistance and the prevalence of the metabolic syndrome in the Framingham offspring cohort. Diabetes Care 2004; 27: 538-546 SM.

  86. Meyer KA, Kushi LH, Jacobs DR, Slavin J, Sellers TA, Folsom AR. Carbohydrates, dietary fiber, and the incident type 2 diabetes mellitus in older women. Am J Clin Nutr 2000; 71: 921-930.

  87. Montonen J, Knekt P, Jarvinen R, Aromas A, Reunanen A. Whole-grain and fiber intake and the incidence of type 2 diabetes. Am J Clin Nutr 2003; 77: 622-629.

  88. Salmeron J, Ascherio A, Rimm EB, Colditz GA, Spiegelman D, Kenkins DJ, Stampfer MJ et al. Diabetes care 1997; 20: 545-550.

  89. Salmeron J, Manson JE, Stampfer MJ, Golditz GA, Wing AL et al. Dietary fibre, glycemic load, and risk of non-insulin dependent diabetes mellitus in women. JAMA 1997; 277: 472-477.

  90. Jeppesen J, Schaaf P, Jones C, Zhou MY, Chen YD, Reaven GM. Effects of low fat, high-carbohydrate diets on risk factors for ischemic heart disease in postmenopausal women. Am J Clin Nutr 1997; 65: 1027-1033.

  91. Mittendorger B, Sidossis LS. Mechanism for the increase in plasma triacylglycerol concentration after consumption of short-term, high-carbohydrate diets. Am J Clin Nutr 2001; 73: 892-899.

  92. Janket SJ, Manson JE, Sesso H, Buring JE, Liu S. A prospective study of sugar intake and risk of type 2 diabetes in women. Diabetes Care 2003; 26: 1008-1015.

  93. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003; 14: 15-19.

  94. Vessby B, Uusitupa M, Hermansen K et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU study. Diabetologia 2001; 44: 312-319.

  95. Summers LKM, Fielding BA, Bradshaw HA et al. Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity. Diabetologia 2002; 45: 369-377.

  96. Vessby B, Gustafsson I-B, Tengblad S et al. Desaturation and elongation of fatty acids and insulin action. Ann NY Acad Sci 2002; 967: 183-195.

  97. Harris WS, Park Y, Isley WL. Cardiovascular disease and long chain omega-3 fatty acids. Curr Opin Lipidol 2003; 14: 9-14.

  98. Noakes M, Clifton P. Weight loss, diet composition and cardiovascular risk. Curr Opin Lipidol 2003; 215: 31-35.

  99. Pirozzo S, Summerbell C, Cameron C, Glasziou P. Advice on low-fat diets for obesity. Cochrane. Database. Syst Rev 2002, CD003640.

  100. Ovarzanek E, SacksFM, Vollmer WM, Bray GA, Miller ER, Lin PW, Karanja NM, Most-Windhauser MM, Moore T et al. Effects on blood lipids of a blood pressure-lowering diet: the dietary approaches to stop hypertension (DASH) trial. Am J Nutr 2001; 74: 80-89.

  101. Erlinger TP, Miller ER, Charleston J, Appel LJ. Inflammation modifies the effects of a reduced-fat, low-cholesterol diet on lipids. Results from the DASH-sodium trial. Circulation 2003; 108: 150-154.

  102. Weinstock RS, Hiliang D, Wadden TA. Diet and exercise in the treatment of obesity: effects of 3 interventions on insulin resistance. Arch Intern Med 1998; 158: 2477.

  103. Fox AA, Thompson JL, Butterfield GE, Gylfodottir U, Mynihan S, Spiller G. Effects of diet and exercise on common cardiovascular disease risk factors in moderately obese older women. Am J Clin Nutr 1996; 63: 225-233.

  104. Pyörälä K, Ballantyne CM, Glumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjeshus J,. Reduction of cardiovascular events by simvastatin in non-diabetic coronary disease patients with and without the metabolic syndrome. Diabetes Care 2004; 27: 1735-1740.

  105. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.

  106. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Amer Coll Cardiol 2003; 41: (Suppl.4): S37-S42.

  107. Ridker PM, Buring JE, Cook NR et al. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events: an 8-year follow-up of 14, t19 initially healthy American women. Circulation 2003; 107: 391-397.

  108. Pannacciulli N, Cantatore FP, Minenna A et al. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Intern J Obes Relat Metab Disord.

  109. Greenberg AS, Mc Daniel ML. Identifying the links between obesity, insulin resistance and beta cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32 (Suppl. 3): 22-34.

  110. McLaughlin T, Abbassi F, Lamendola C et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002; 106: 2908-2912.

  111. Fuchgott RF, Zwadsky JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.

  112. Hamdy O, Ledbury S, Mullooly C, Porter S, Ovalle K, Moussa A, Caselli A, Caballero AE, Economides PA, Veves A, Horton ES. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26: 2119-2125.

  113. Ricker PM. Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin Cardiol 2003; 26: 1139-1144.

  114. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM et al Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention study. Circulation 2001; 103: 357-362.

  115. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRCB/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: A randomized placebo-controlled trial. Lancet 2003; 361: 2005-2016.

  116. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.

  117. Marx N, Froehlich J, Siam L, Itnner J, Wierse G, Chmidt A, Scharnagl H, Hombach V, Koenig W. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-288.

  118. Maerz A, Hombach V, Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-1957.

  119. Pearson TA, Blair SN, Daniels SR et al. American Heart Association guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-391.




2020     |     www.medigraphic.com